Lam M, Zhu JW, Tadrous M, et al. - Researchers conducted this systematic review and meta-analysis of 11 studies to examine the link between topical calcineurin inhibitor (TCI) use and risk of malignant neoplasms vs nonactive and active comparator groups. They analyzed observational studies assessing the link between treatment with TCIs (ie, tacrolimus and pimecrolimus) and the occurrence of cancer with nonactive or active comparators. They found no link between treatment with TCI and risk of cancer overall or skin cancer. TCI use was shown to be associated with an elevated lymphoma risk. Although a positive link between TCI use and lymphoma was evident, the low absolute risk of lymphoma makes the potential elevated risk due to TCI use for any individual patient very small.